Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch & Lomb To Spur Lens Care Sales With New Solution Launch

This article was originally published in The Tan Sheet

Executive Summary

Bausch & Lomb plans to boost top line growth in its lens care category with the introduction of a new "first of its kind" lens solution next year

You may also be interested in...



Bausch & Lomb

U.S. Patent & Trademark Office grants Bausch & Lomb's patent for Ocuvite PreserVision antioxidant mineral formula Dec. 9. The same day, the Rochester, N.Y.-based company filed lawsuits in U.S. District Court against Alcon Labs, GNC, Leiner and Rexall Sundown, alleging that their respective eye vitamin products infringe on its patent rights. A study in the Archives of Ophthalmology November issue found that if, over the next five years, all those at risk of developing age-related macular degeneration took Ocuvite PreserVision, more than 300,000 people would avoid advanced ADM and any associated vision loss (1"The Tan Sheet" Nov. 17, 2003, p. 11). At a recent Bear Stearns conference, B&L CFO Steve McCloskey predicted the Ocuvite brand, which had around $50 mil. in sales in 2002, could reach $100 mil. to $200 mil. in the next few years (2"The Tan Sheet" Sept. 15, 2003, p. 6)...

Bausch & Lomb

U.S. Patent & Trademark Office grants Bausch & Lomb's patent for Ocuvite PreserVision antioxidant mineral formula Dec. 9. The same day, the Rochester, N.Y.-based company filed lawsuits in U.S. District Court against Alcon Labs, GNC, Leiner and Rexall Sundown, alleging that their respective eye vitamin products infringe on its patent rights. A study in the Archives of Ophthalmology November issue found that if, over the next five years, all those at risk of developing age-related macular degeneration took Ocuvite PreserVision, more than 300,000 people would avoid advanced ADM and any associated vision loss (1"The Tan Sheet" Nov. 17, 2003, p. 11). At a recent Bear Stearns conference, B&L CFO Steve McCloskey predicted the Ocuvite brand, which had around $50 mil. in sales in 2002, could reach $100 mil. to $200 mil. in the next few years (2"The Tan Sheet" Sept. 15, 2003, p. 6)...

Bausch & Lomb

U.S. Patent & Trademark Office grants Bausch & Lomb's patent for Ocuvite PreserVision antioxidant mineral formula Dec. 9. The same day, the Rochester, N.Y.-based company filed lawsuits in U.S. District Court against Alcon Labs, GNC, Leiner and Rexall Sundown, alleging that their respective eye vitamin products infringe on its patent rights. A study in the Archives of Ophthalmology November issue found that if, over the next five years, all those at risk of developing age-related macular degeneration took Ocuvite PreserVision, more than 300,000 people would avoid advanced ADM and any associated vision loss (1"The Tan Sheet" Nov. 17, 2003, p. 11). At a recent Bear Stearns conference, B&L CFO Steve McCloskey predicted the Ocuvite brand, which had around $50 mil. in sales in 2002, could reach $100 mil. to $200 mil. in the next few years (2"The Tan Sheet" Sept. 15, 2003, p. 6)...

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel